RecruitMe Clinical Trial

A Phase II study of chemotherapy and immune checkpoint blockade with Pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma
A study for patients with gastric cancer using study drug Pembrolizumab
Sponsor:Merck Sharp & Dohme Corp.
Enrolling:Male and Female Patients
IRB Number:AAAQ9871
U.S. Government ID:NCT02918162
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This is a research study is evaluating the addition of immune therapy to standard chemotherapy for localized gastric cancer. The current treatment for localized gastric cancer is to have chemotherapy and surgery, usually the chemotherapy is given before and after surgery. However, despite surgery the cancer may return in many people. The purpose of this study is to determine if adding immune therapy to chemotherapy will increase the likelihood of eliminating the cancer and preventing the tumor from returning. The experimental therapy, pembrolizumab, works by activating the immune system through modification of immune checkpoints. In this study, we will utilize pembrolizumab both with chemotherapy and for up to 1 year after surgery as maintenance therapy. We will monitor subjects to determine if the combination therapy is safe and if it is effective in preventing tumors from recurring.

Do You Qualify?
Have you been diagnosed with gastric cancer?YesNo
Are you able to walk and care for yourself and do light physical activity like light housework or office work?YesNo
Submit
Cancel
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162